Testing dalpiciclib with or without entinostat and letrozole for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is testing a combination of three drugs (dalpiciclib, entinostat, and letrozole) for women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. It aims to see if adding these medications before surgery can help shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 74, and if you are still having periods, you are willing to take medication to suppress your ovaries.
- Your breast cancer is hormone-receptor-positive (ER+) and HER2-negative, and it can be seen on a scan.
- You have not had any previous treatment for breast cancer, including chemotherapy, hormone therapy, or targeted therapy.
- You are able to swallow pills, and your heart, liver, and kidney function are normal enough for the study.
- You are willing to have a biopsy and to follow the study plan, including using birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This trial tests a combination of two drugs, dalpiciclib and letrozole, as maintenance therapy after first-line chemotherapy for HR-positive, HER2-negative metastatic breast cancer. The goal is to see if this combination helps keep the cancer from growing.
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
This study tests a new combination of treatments given before surgery for breast cancer that is hormone-receptor positive and HER2-low. The goal is to see if giving these drugs before surgery can shrink tumors and improve outcomes. You might be eligible if you have not yet had any treatment for breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.